Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHJV0X)

• Drug Name: Pertuzumab Drug Info
• Synonyms: Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1] , [2]

• Cross-matching ID: TTD Drug ID: DMHJV0X

Molecule-Related Drug Atlas

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[5]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[6]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[7]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[8]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[9]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[10]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[11]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[12]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[13]
HKI-272	DM6QOVN	Breast cancer	2C60-2C65	Phase 3	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Inhibitor	[3] , [4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5046).
• [2] Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71.
• [3] Clinical pipeline report, company report or official report of Roche (2009).
• [4] Pertuzumab. Drugs Fut 2008, 33(2): 123 ISSN 0377-8282.
• [5] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [7] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [8] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [9] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [11] Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [14] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.